JJ
CTNM

Johnson & Johnson’s Contineum Therapeutics CTNM Stock Holding History

Johnson & Johnson’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.8M Hold
1,979,173
– – 3.96% 6
2025
Q4 		$22.6M Hold
1,979,173
– – 4.08% 6
2025
Q3 		$23.3M Hold
1,979,173
– – 4.61% 7
2025
Q2 		$8.13M Hold
1,979,173
– – 2.43% 8
2025
Q1 		$13.8M Hold
1,979,173
– – 4.04% 8
2024
Q4 		$29M Hold
1,979,173
– – 7.51% 5
2024
Q3 		$37.9M Hold
1,979,173
– – 8.86% 4
2024
Q2 		$34.9M Buy
+1,979,173
New +$31.9M 8.7% 5

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Johnson & Johnson's CTNM Position: Q1 2026 in Review

Johnson & Johnson held its Contineum Therapeutics (CTNM) position steady in Q1 2026 at 1,979,173 shares worth $25.8M. The position accounts for 3.96% of the portfolio, ranked #6.

Johnson & Johnson first reported a position in CTNM in Q2 2024 and has held it in 8 quarters since. The position peaked at $37.9M in Q3 2024. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Johnson & Johnson held 1,979,173 shares of Contineum Therapeutics worth $25.8M as of Q1 2026.
  • Johnson & Johnson left its Contineum Therapeutics share count unchanged in Q1 2026.
  • Contineum Therapeutics made up 3.96% of Johnson & Johnson's portfolio in Q1 2026, its #6 holding.
  • Johnson & Johnson first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Johnson & Johnson's Contineum Therapeutics position peaked at $37.9M in Q3 2024.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Johnson & Johnson's 13F filing for Q1 2026, filed 13 May 2026.